Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension

American Heart Journal

Volumn 140, Issue 6, 2000, Pages 848-856

  Brown, David W ^a   Giles, Wayne H ^b   Croft, Janet B ^b  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DEMOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SURVIVAL;

EID: 0033675191     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.111112     Document Type: Article

References (20)

1. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Heart Study
2. Left ventricular hypertrophy as a risk factor: The Framingham experience
3. Left ventricular hypertrophy and mortality: Results from the Framingham Study
4. The prognostic effects of hypertensive left ventricular hypertrophy in a population with low prevalence of hypertension and low plasma cholesterol
5. Why is left ventricular hypertrophy so predictive of morbidity and mortality?
6. Potency of vascular risk factors as the basis for antihypertensive therapy
7. Left ventricular hypertrophy as a risk factor in arterial hypertension
8. Methodology of ECG interpretation in the Dalhousie Program: NOVACODE ECG classification procedures for clinical trials and population health surveys
9. Test of the National Death Index
10. Comparability of mortality follow-up before and after the National Death Index
11. Utility of the National Death Index for ascertainment of mortality among Cancer Prevention Study II participants
12. Electrocardiographic estimate of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the Epidemiologic Follow-Up Study of the First National Health and Nutrition Examination Survey
13. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease
14. Fosinopril reduces left ventricular mass in untreated hypertensive patients: A controlled trial
15. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
16. Is the electrocardiogram still useful for detection of left ventricular hypertrophy?
17. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: Validation with autopsy findings
18. Left ventricular hypertrophy in black and white hypertensives: Standard electrocardiographic criteria overestimate racial differences in prevalence
19. Validity of electrocardiographic estimates of left ventricular hypertrophy and mass in African Americans (The Charleston Heart Study)